Methadyne can be administered for analgesia of moderate to severe pain in dogs and cats, to provide neuroleptanalgesia in combination with a neuroleptic drug and as part of a patient’s premedication protocol prior to general anaesthesia.
The new presentation will now be available alongside the 10ml vial to give greater flexibility and to help reduce drug wastage and streamline controlled drug stock management.
Jurox says Methadyne has proven compatibility when combined in the same syringe with other aqueous solutions for injection containing acepromazine as maleate and medetomidine and dexmedetomidine as hydrochlorides.
Methadyne has a shelf life of 24 months unbroached, and 28 days broached. After broaching, the bung can be punctured to draw up a dose of methadone as many times as required in 28 days.
Dan Cripwell MRCVS, senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution in our multidose methadone formulation, which is now available in both 5ml and 10ml vials.
"We constantly strive to provide the veterinary profession with first class clinical and technical support and, in this instance, we were able to assess what improvements could be made to our existing drug portfolio and respond to the profession’s feedback to help reduce wastage of controlled drugs when they are needed in smaller volume."
For further information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
The video has already been viewed a staggering 4.6 million times.
In the Facebook post and subsequent comments Jodie explained that her 12-year-old rescue bulldog collapses every couple of months. She highlights the dangers of walking flat-faced dogs in hot weather and the choking hazards that eating can present for dogs with an abnormal soft palate.
BVA President Gudrun Ravetz, said: "This is a very distressing video that demonstrates just how serious BOAS (brachycephalic obstructive airway syndrome) is as a condition for those dogs living with it.
"No dog should have to endure the distress of regularly collapsing, though sadly this is a reality for many flat-faced dogs. We would strongly advise anyone with a pet suffering these symptoms to talk to their vet urgently to agree the best way to ensure the health and welfare of their pet. This may include opting for surgery and will definitely include taking special measures in hot weather.
"BVA has been highlighting the significant health problems suffered by flat-faced dogs, such as bulldogs, and asking potential owners to choose healthier breeds or crossbreeds."
Hopefully, Jodie's video might just cause a few potential owners to do precisely that.
Photo: Facebook/Jodie Marsh
A test by the Australian Racing Forensic Laboratory (ARFL) of samples from a newly prepared batch of Bova’s 100mg/ml injectable omeprazole formulation did not detect testosterone, and Racing New South Wales has now released a statement that the product can continue to be used in racehorses following the guidance of Australian Commonwealth and State legislation.
Nick Bova, managing director of Bova UK, said: "Traces of testosterone in the previous batch were less than one millionth of the internationally accepted standard for impurities.
"Independent experts confirmed that there could be no adverse effects on equine health or equestrian sport, however, we have taken steps to identify and completely eliminate the excipient ingredient that contained traces of testosterone."
Nick added: "Bova can confirm that new batches of this product will not contain the previous trace levels of testosterone and therefore Bova are confident there will be no antidoping issues, no matter what the equestrian pursuit is."
The company has identified that inconsistencies in the cleaning process have led to low levels of a previous product being carried over into the Stresnil batch no PP1466, EXPIRY: 30-09-2019.
For more information about the recall, contact Matthew Edwards: elanco_orders@lilly.com or telephone: 01256 779519.
An Oxford woman has launched Veterinary Thermal Imaging Ltd, a company which claims to be the first in the UK to use thermal imaging to help identify and monitor injury and illness in domestic pets.
Helen Morrell, 34, uses an FLIR infrared camera to detect physiological changes in animals. She says the technique is traditionally only used in top competition and racing stables, and can highlight health problems, including tendon, joint and nerve damage, which would otherwise be undetectable without invasive and expensive procedures such as x-rays and MRI scans.
Helen said: "I became interested in thermal imaging after being made redundant from my job in financial services. I'd studied Animal Science at Newcastle University when I was younger and I viewed the redundancy as the perfect opportunity to return to the industry.
"I realised that there were only a few people in the country who offer thermal imaging, and then only to horses. It's a really emerging technique that has huge potential and is already widely used in the US across all animals, including domestic, livestock, zoo and wildlife. It seemed that there was a huge gap in the market in this country."
Helen contacted leading experts in the US and became the first British woman to be accepted onto the thermal imaging course at Florida University. She said: "I knew I wanted to use the technique on domestic pets and the experts in the field were all in America. It made sense to me to get the training there and make sure I was at the top of my game."
Helen says she is currently working with a three-year-old terrier called Jack who is suffering from muscular atrophy caused by a locking patella. Although the thermal imaging didn't diagnose the problem, she says it is allowing the monitoring of his treatment and providing an objective assessment of the muscles affected by the injury.
Virbac has launched the UK's first blood test for BPH (benign prostatic hyperplasia) which, according to the company, will provide practices with a significant opportunity to improve the prognosis for many of the UK's male dog population that suffer from the condition but go undetected.
Odelis CPSE is the first ELISA test to screen, diagnose and monitor BPH. Virbac Product Manager Chris Geddes MRCVS believes that the test is an important step forward in the diagnosis of the condition: "Not only does Odelis CPSE provide a simple and reliable alternative to rectal palpation, it will also give an objective measure of the degree of BPH present."
According to Chris, although BPH affects over 80% of entire male dogs over five years old, many go undiagnosed until the condition is advanced and symptoms become apparent. "Whilst regular screening is recommended in elderly dogs, rectal palpation is not a particularly popular process to carry out routinely without the presence of symptoms.
"We know that currently diagnosis of BPH falls well below the incidence, however this new test means that practitioners can now routinely monitor 'at-risk' dogs, e.g. stud males, elderly dogs, and those with a previous history of BPH. Bloods can be taken at practice visits, or routinely at vaccination boosters or annual health checks for example. So the test is not only good for animal welfare, it's a great business opportunity too".
There are three labs in the UK selected to carry out the test: Biobest; Carmichael Torrance; and Nationwide Laboratories.
Information is being mailed to all practices. Your first test free, and all positive test results recorded up to 31st October will receive a 'buy one get one free' promotion for Ypozane (osaterone acetate), the first-line treatment for BPH.
Alternatively, contact your local Virbac territory manager, or call Virbac on 01359 243243.
The popular novels, which were written by real life Yorkshire vet Alf Wight, depicted Herriot - and others like him - as working all hours, doing favours for clients free of charge and being paid in cake, all with scarcely a mention of how he made ends meet.
This misguided image still informs expectations of the profession today, they say.
Henry Tremaine, a specialist in equine surgery and dentistry, said: "The nostalgic thing is of this romantic life driving around in an old car being appreciated by the clients - but actually the reality is working very long hours in stressful conditions with poor reward, being poorly equipped, and with unappreciative clients.
"That’s being consigned to history - gradually - but I think the public still cling onto the notion that that’s what a vet’s life is."
His comments echo those of BSAVA President, Sue Patterson, who earlier this year blamed James Herriot for the assumption among some clients that vets' love of animals would make them prepared to work for nothing: "I think James Herriot is to blame because we’re all supposed to love animals and work for nothing, but we all run businesses."
At the BEVA Congress earlier this month, equine vet and congress speaker, Ben Mayes, who graduated in 1992, also criticised the Herriot legacy for making it harder for vets to achieve a good work-life balance: "We’ve been left in that Herriot mentality, and it was a nightmare."
This week's edition of the Vet Record has six case studies of veterinary surgeons who have pursued careers through non traditional routes, including Peter Harlech Jones, Daniella Dos Santos, (pictured right), and Enrique Vega.
Daniella Dos Santos said: "James Herriot continues to inspire vets and future vets, and we know from our own research that he along with other vets in literature is still very popular across the profession.
"At the same time, the profession is very different to what was depicted in the age of Herriot and it continues to undergo significant change. We need to make sure that there is a diverse range of role models in place that reflect modern demographics and modern ways of working while continuing to inspire future generations of vets."
Adele Waters, Vet Record editor, added: "James Herriot may be a popular cultural figure, but he is 70 years out of date and we should retire him gracefully. With 60 per cent of UK vets being female, Herriot is no longer representative of the modern working vet, and today we should really be talking about Jane Herriot instead."
Vetsonic has launched Otimectin vet, an ivermectin-based topical preparation for the treatment of Otodectes cynotis infections in cats.
The new product offers a once-weekly dosing alternative to traditional ear mite treatments, which commonly require twice daily administration over 7 to 21 days.
Presented as a gel in a 10g tube complete with application spout, Otimectin vet is a 1 mg/g ivermectin preparation. It does not contain an antibiotic or steroids.
Davies says its Cardiac Electrophysiology Laboratory, headed by Pedro Oliveira (pictured right), is one of only four centres in the world to perform the procedure, and it has usually required human medical support. The fact that they've been able to operate independently means the procedure should now start to become more readily available.
The procedure involves introducing special catheters via peripheral veins into the heart, where they are used to record the electrical activity of the heart muscle, thereby allowing the identification of the source and mechanism of cardiac arrhythmias.
Once the abnormal tissue is found, it is destroyed using intense localised energy delivered by another specialised catheter: radiocatheter ablation.
This technique is common in human medicine but very rare in veterinary medicine because of the level of specialisation needed.
In the past, the cardiology team at Davies needed the support of a consultant and a cardiac physiologist from the human field to help carry out the surgery. Having now done it unaided, Pedro is confident that in time Davies will be able to help considerably more patients, promptly after diagnosis.
Pedro said: "In three years we have treated one cat and 19 dogs. Several cases did not survive long enough for surgery despite a waiting time of only a few days to up to two weeks from referral to the procedure. Most of these dogs were puppies. This is incredibly frustrating as if performed early these procedures are curative for most patients."
Davies says that to date it has had a procedural success rate of 100%, with recurrence of the arrhythmia in just one dog. The remaining dogs were cured from their arrhythmias and recovered fully except for two dogs that had sustained too much heart muscle damage and continued to suffer from congestive heart failure.
Pedro added: "Hopefully in the future severe muscle damage can be avoided by early referral when the arrhythmia is detected. If you diagnose a cardiac arrhythmia, especially supraventricular tachycardia, please consider this treatment option because it is very likely to be curative."
The Davies cardiology team can be contacted at cardiology@vetspecialists.co.uk.
Incidentally, Pedro has also co-authored (with Ruth Willis and Antonia Mavropoulou) a new book on electrocardiography. Guide to Canine and Feline Electrocardiography will be published in September 2018 and is available for pre-order on Amazon now, priced at £89.99.
Dr De Armas Jimenez faced four charges against him, that:
On or around 22 April 2022 or 23 April 2022, in relation to a cat, he a) failed to obtain informed consent to sedate/anaesthetise the cat and/or did so without the owner’s consent (admitted), b) failed to take adequate steps when the cat required emergency attention (admitted), and c) failed to provide adequate details to the owner following the cat’s death (admitted).
On or around 22 April 2022 or 23 April 2022, he a) failed to record adequate clinical record details of the cat’s sedation/anaesthetic (admitted), b) recorded when the cat became cyanotic, that i) a tube had been passed in order to intubate (proved not to have occured) and ii) chest compressions had been given when this was not the case (not proved that it did not happen), and c) failed to make adequate clinical records in relation to differential diagnoses and proposed treatment plan (not proved).
That his conduct in relation to charge 2(a) and/or 2(b) was a) dishonest and/or b) misleading. (Admitted his conduct was both dishonest and misleading in relation to 2(a), and the Committee found proved that his conduct was dishonest and/or misleading in relation to 2(b)(i)).
Between 22 April 2022 and 23 April 2022, he failed to have any professional indemnity insurance in place (admitted).
Dr De Armas Jimenez admitted most of the charges again him.
The Committee found that his actions had breached a number of sections of the RCVS Code of Conduct for Veterinary Surgeons and amounted to serious professional misconduct.
In deciding on a sanction, the Committee took into account the aggravating factor that Dr De Armas Jimenez had caused actual harm to the animal.
Mitigating factors included that he had no previous disciplinary history, that he had been working for eight years as a veterinary surgeon in the UK without complaint, that he admitted most of the charges, that he'd made subsequent efforts to avoid repetition by no longer working night shifts or locuming, and finally that the incident related to one animal.
The Committee also noted that he'd shown appreciable insight and remorse, and took into account positive character references.
Paul Morris, chairing the Disciplinary Committee and speaking on its behalf, said: “Whilst the misconduct in this case involved breaches of the RCVS Code, caused serious harm to both the cat and the client, and involved dishonesty which was concealed, the Committee decided that a lengthy suspension could take account of the seriousness of these matters and meet the wider public interest.”
He added: “In deciding on this period of suspension, the Committee took into account both mitigating and aggravating factors and the mitigation Dr De Armas Jimenez had put before it.
"It was not persuaded that a shorter period of suspension would properly reflect the seriousness of the proven misconduct.
"It concluded that this period of suspension had a deterrent effect and sent a signal as to how serious the Committee had found the misconduct to be.
"It also took into account Dr De Armas Jimenez’s remorse and insight.
“However, in order that the wider public interest was upheld and to reflect the Committee’s view regarding the seriousness of the proven misconduct, the Committee determined that the proportionate sanction and period of suspension should be a suspension order of eight months.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings/
Merck, part owner of Merial, has announced a merger with Intervet Schering-Plough.
However, rumours that Merck plans to sell its 50% stake in Merial and move forward with Intervet Schering Plough are incorrect, according to Merck spokespeople.
They'll have to start thinking about what to call themselves soon. Merial-Intervet-Schering-Plough is a bit of a mouthful.
This brings the total number of UK pet insurance companies that offer FirstVet veterinary consultations with their policies to 19, including Co-op, Costco, PETtrac, ManyPets and CoverMyPet.
Launched in 2016, FirstVet now operates in seven markets: the UK, US, Germany, Norway, Denmark, Finland, and Sweden, delivering more than 30,000 consultations per month.
David Prien, CEO at FirstVet said: “FirstVet was founded with the passionate goal of making pet care more accessible for everyone.
"Our new partnership with Petwise Senior reflects our commitment to ensuring all pets, including senior pets, receive the best possible care they deserve after all those years of companionship, friendship and loyalty.
"Since launching, FirstVet has helped nearly one million pet owners around Europe.
"I really look forward to supporting Petwise Senior pets through our FirstVet app and to the many stories that will come from this great partnership!”
The machine-washable wound/bandage protector is available in denim blue, in five different sizes.
Pads, sold separately, can be added to pockets in the Head Cover for additional protection. Alternatively, the pockets can be used to hold a dog’s ear to prevent wound fluids and ointments from sticking to the fur.
The company has also announced the launch of the new Medical PetS Boot, a waterproof paw protector which, unlike the alternatives, comes in a variety of sizes and is firmly held in place with both velcro straps and a drawstring.
For more information, visit: https://www.jakmarketing.co.uk or ring 01347 878697
Merial has announced the launch of Oncept IL-2, the first veterinary immunotherapeutic product in Europe for the management of cancer in pets.
Described by the company as a true breakthrough in the field of veterinary oncology, Oncept IL-2 is an adjunct immunotherapy for feline fibrosarcoma.
Merial says the product is based on recombinant canarypox vector technology it developed collaboratively with veterinary oncologists, and which is used in several of its vaccines, including PUREVAX FeLV and PUREVAX Rabies.
Oncept IL-2 is indicated for cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in order to reduce the risk of relapse and to increase the relapse-free interval. It should be used in addition to surgery and radiotherapy.
Kevin Whelan, Merial's Technical Manager said: "Following injection around the tumour surgery site, the recombinant canarypox vector virus enters the cat's cells, which then produce interleukin-2. The presence of this cytokine stimulates an anti-tumour immune response by a variety of mechanisms, including the induction of T-lymphocytes and natural killer cells."
In a field efficacy trial, a treatment course with Oncept IL-2 (consisting of 6 subcutaneous administrations in the tumour bed over a 7-week period), as an adjunct to surgery and radiotherapy, was shown to significantly reduce the risk of relapse and to increase the time to relapse.
The product is available in packs of 6 doses, which is sufficient for a treatment course. Please contact your local Merial Territory Manager for further information or email oncept@merial.com
Elanco Animal Health has launched AviPro Salmonella Duo, a new live vaccine which provides simultaneous protection against S Enteritidis and S Typhimurium in poultry.
Jessica Cross, Elanco's poultry veterinary consultant said: "AviPro Salmonella Duo is the first vaccine to have both Salmonella strains in the same vial and also the first to be licensed for turkeys and ducks as well as chickens."
Unlike inactivated vaccines which are administered by injection, AviPro Salmonella Duo is administered in the drinking water. Elanco says this offers producers significant advantages since the oral route allows mass administration without stressing the birds, saving labour and improving welfare. A three-dose programme provides immunity throughout lay.
The new vaccine also provides an eight-week increase in the period of immunity over its predecessor, to 62 and 68 weeks of age for S Typhimurium and S Enteritidis respectively.
Jessica said: "This development represents the third generation of vaccines, moving on from the early dead vaccines, individual live vaccines to the bivalent product. Producers will welcome the simplified administration it offers."
The BEVA has welcomed the news, whilst expressing its concern that the drug was suspended without consultation with the veterinary profession in the first place.
Jon Pycock, BEVA President said: "It remains a concern to BEVA that this mechanism was not put in place before the suspension of flunixin was imposed. Contrary to assertions by the VMD, wholesalers were unable to meet the demands of the veterinary profession and clinical use of this medicine was disrupted within 24 hours of the VMD’s initial announcement.
"We are surprised by the Regulator’s lack of awareness of availability in the supply chain and question why there was no consultation with the veterinary sector before the suspension was enacted. The VMD has been aware of this issue since March 2018 and it appears that no contingency was put in place to consider the animal welfare impact of this decision until it was too late."
BEVA Junior Vice President and Specialist in Equine Surgery Tim Mair continued: "Flunixin is a unique medicine in managing pain and sepsis in horses with colic. The VMD appeared to believe that this medicine could be substituted for other veterinary medicines and this is simply not the case. The release of stock from manufacturers is a short-term solution and, looking forward, we would like assurances that the VMD will fast track applications for the modification of product licenses to ensure that equine vets have continued access to these products."
Professor Kate White, Senior Vice President of the Association of Veterinary Anaesthetists added: "Provision of pain relief is essential to maintain animal welfare. The loss of these products would hinder the work of vets working with horses and donkeys and in zoos where they are first line drugs for the management of pain. Use of flunixin in these animals can be undertaken safely with no impact on human health."
Stock of flunixin held by manufacturers will be distributed alongside a ‘caution in use’ letter that will explain the restricted use of this product. BEVA is reminding all equine vets that the horse’s food chain status must be checked when using this product – either using the paper passport or the recently launched chip checker on the central equine database website.
The association has written a joint letter with the British Equine Veterinary Association and the Association of Veterinary Anaesthetists to the Veterinary Medicines Directorate asking for licence to be granted to specials manufacturers to produce isoflurane whilst the shortage persists, which Zoetis forecasts will be until March 2019.
In addition, the association's incoming Chair of the BSAVA Scientific Committee, Ian Self, an RCVS Specialist in Veterinary Anaesthesia and Analgesia has provided advice to support practitioners looking for alternative anaesthesia options, available here: https://www.bsava.com/News/ArticleID/2535/Isoflurane-supply.
The association has also made Chapter 14 of its online edition of the BSAVA Manual of Canine and Feline Anaesthesia and Analgesia 3rd edition free to access until the end of March 2019. The manual contains further information on alternative solutions such as TIVA (Total Intravenous Anaesthesia protocols) which some will be unfamiliar with.
The manual can be accessed here: https://www.bsavalibrary.com/content/chapter/10.22233/9781910443231.chap14
Dr Crawford sent the email to his client, Mrs X, on 15 July 2014, the day on which Mrs X’s horse was due for insemination using horse semen supplied from a horse in Germany. However, the semen had arrived without the Intra Trade Certificate, a requirement for intra-EU inseminations, and so Dr Crawford proceeded to contact the Department for the Environment, Food and Rural Affairs (Defra) for alternative authorisation.
Just after 4:30pm on that day, Mrs X received a text from Dr Crawford advising her that he had received authorisation from the AHVLA, and would forward to Mrs X the AHVLA authorisation email. It later transpired that that the email had in fact been fabricated by Dr Crawford using an email that he had previously received from the AHVLA regarding another matter.
Dr Crawford faced the following charges:
Fabricating an e-mail purporting to be from the veterinary officer at the AVHLA, authorising use of semen from a horse for insemination, when in fact he had not received such authorisation.
Dishonesty in relation to the e-mail described above.
His conduct gave rise to spread of infectious disease which had the potential to affect equine animal health and welfare in the region.
Dr Crawford admitted the first two charges, but denied that his actions had given rise to the risk of disease.
The Committee found the first two charges proved, and moved on to determine the facts of the third charge. They took into account that Dr Crawford had received verbal confirmation that the semen was safe, and that the health papers had been stamped accordingly. He had not, however, seen a copy of this certificate and so there was no guarantee that the semen was safe to use at the time he sent the fabricated email. On consideration of the facts, the Committee found this charge proved, as Mrs X’s mare could have been infected and subsequently could have adversely affected equine animal health and welfare in the region.
They also found that his entire course of action had fallen far short of what is expected of a veterinary surgeon, and that it amounted to disgraceful conduct in a professional respect.
When determining sanction, the Committee took into account a number of aggravating factors, namely the risk of injury to animals, an element of pre-meditation, a disregard for the role of the AHVLA, impersonating a fellow veterinary surgeon, and intending to deceive a veterinary surgeon as well as a member of the public.
It did also, however, take into account the mitigating factors – that there was no injury to the animal, and that it was a single isolated incident from which Dr Crawford did not stand to make any financial gain.
The Committee therefore decided to order the Registrar to suspend Dr Crawford’s registration for 12 months.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee did consider whether to remove Dr Crawford from the Register. However, in light of the significant mitigation in this case, the fact that this was an isolated incident in an otherwise unblemished career, together with his acceptance from the outset that he had been dishonest and his assurance that he would never behave in this way again, the Committee decided that in all the circumstances to remove him from the Register would be disproportionate."
Dr Crawford can lodge an appeal with the Privy Council within 28 days of being notified of the Disciplinary Committee's decision.
Insistor, which contains methadone hydrochloride, is now available in the UK in a 10ml bottle for use in dogs and cats, POM-V.
Chanelle says Insistor can also be used for analgesia in animals experiencing post-operative pain or pain caused by trauma.
Chanelle’s Head of Sales and Marketing, Killian Gaffney, said: "Insistor joins Chanelle’s extensive anaesthetic, analgesic and sedative range. Insistor (methadone hydrochloride), Butador (butorphanol) and Bupaq (buprenorphone) complete the 360° Opiod suite of products from Chanelle.
"We are pleased to add Insistor to our portfolio of products, which builds the offering to veterinary surgeons of anaesthetic products."
The winning images were selected from nine finalists, shortlisted from hundreds of entries that were taken by vets, both in their professional and private lives.
And the winners are ...
Sophie said: “I was very surprised to win with my photo of a newborn calf standing next to me during the closing phases of surgery.
"I'm not that slow at suturing up, it’s just the calf was very alert and standing before I finished!
"For me this photo encapsulates the best parts of farm vetting: prompt decisions, safe handling, great outcomes, teamwork.
"I’m very proud to be a farm vet and exceptionally pleased this photo will be seen by current farm vets and hopefully will inspire future farm vets from all walks of life to pursue a veterinary career.”
Katherine, who is a third year Veterinary Medicine student at the Royal Veterinary College, said: “I'm absolutely delighted to have my photograph selected as the winner of the category, especially against such impressive entries.
"I was on a morning visit to a game reserve with a local vet in South Africa, when the sunrise highlighted the small oxpeckers on the backs of the giraffes, frantically flying to and fro.
"With the giraffe curiously watching us, I managed to capture the moment all three birds landed on its back, creating the image representing all creatures great and small.”
Sam Price said: "I took the image of my dog, Winnie, while on a campervan trip on the north coast of Ireland.
She loves nothing more than a beach day as you can see so I felt this was a fitting photo for the brief.
Thankfully there was a rare bout of sunshine on the day which made for some nice lighting and Winnie is pretty photogenic, which always helps!"
BVA President Malcolm Morley said: “The winning images stood out to us for many reasons, but we particularly liked how each one captured the essence of the category it was entered into; Sophie’s image of a c-section on a cow was so touching and really demonstrates the daily life of many of our valued farm vets; Katherine Edmondson’s photograph of the giraffe and red-billed oxpeckers was stunning but also truly embodied the All creatures great and small element; while Sam Price’s photo of Winnie the dog literally jumping for joy stole our hearts and genuinely made us all break out in smiles.
“Congratulations to all the winners, and also a huge well done to all the finalists as well, it was a really tough decision but you should be proud of the incredible photographs you entered and your talents.”
In one of the finest pieces of investigative journalism since Watergate, the erstwhile-criminal-law-barrister-cum-tv-reporter Robert Rinder discovered that he could buy a wormer for his dog from some online retailer for half the price that he'd bought it at his veterinary practice.
Incensed by his discovery that things can cost less online, Mr Rinder then asked a handful of pet owners whether they could recall seeing a sign at their practice to advise them that they could buy things cheaper elsewhere.
None could. But then I'll bet if he asked whether they could remember a sign for the toilet, they'd have struggled.
Still, by now certain they'd found evidence that pet owners are being 'fleeced', Watchdog then rang 70 practices to ask for the price of some common drugs and then compared them to the prices being offered by online retailers.
Their research confirmed the awful truth. Some places really do charge more than others.
Honestly, who, in a million years, would have guessed?
BBC Watchdog (piece starts at 42:25).
Zoetis has announced the launch of Versican Plus, a vaccine range for dogs in the UK and throughout Europe.
Versican Plus is the only vaccine to combine DHPPi + L4 in a single injection1, something which Zoetis says is the fruit of several years research and development.
The leptospirosis components of the vaccine have been designed to meet the challenges of both existing and emerging types.
According to the company, Versican Plus is the only tetravalent leptospirosis vaccine to deliver prevention against clinical signs and urinary excretion of established (Icterohaemorragiae and Canicola) and emerging (Bratislava and Grippotyphosa) canine leptospirosis (except Grippotyphosa where prevention of clinical signs occurs but with a reduction in urinary excretion).
Zoetis also highlights the advantage this vaccine brings is in its viral components. Versican Plus utilises a new CPV-2b strain, the most prevalent strain in the UK2, to prevent clinical signs, leucopoenia and viral excretion caused by Parvovirus.
Practices using Versican Plus will have the ability to provide protection at the earliest opportunity, as it has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to Parvovirus, Distemper and Adenovirus at levels equal or higher to those likely to be encountered under field conditions.
As a result Versican Plus can be used from 6 weeks of age with an early onset of immunity being achieved for Parvovirus, Distemper and Adenovirus at 9 weeks. Parainfluenza and Leptospirosis immunity follow shortly thereafter at 12 and 13 weeks respectively.
Following primary vaccinations three to four weeks apart Versican Plus provides 3 years duration of immunity for Parvovirus, Distemper and Adenovirus.
Ned Flaxman, Zoetis UK Companion Animal director said: “Our research and development team has taken many different aspects of vaccination into account to create Versican Plus. As well as offering comprehensive protection in accordance with the current epidemiological situation, the vaccine is also convenient to use. It offers a flexible primary vaccination course with an early finish option from 9 weeks, important for early socialisation reasons.”
For further information, visit www.zoetis.co.uk/versicanplus, contact your Zoetis Account Manager or telephone 0845 300 8034.
References
The chewable, prescription-only tablet contains sarolaner, which kills fleas and ticks; moxidectin, for the prevention of heartworm, lungworm disease and for the treatment of some intestinal worms; and pyrantel embonate, for the treatment of gastrointestinal nematodes (hookworms and roundworms).
Professor Tim Geary, BSc PhD, Professor Emeritus, Institute of Parasitology, McGill University, Canada, and Professor, School of Biological Sciences, Queen’s University, Belfast, a consultant to Zoetis, said: “Serious diseases that are preventable and of increasing prevalence threaten dogs in Canada and Europe. Simparica Trio today offers a better solution to preventing and controlling these parasites against the concern of their increasing prevalence."
Rob Kelly, President, International Operations at Zoetis said: "With Simparica Trio, we bring to market an advanced parasiticide solution, helping to deliver improved client satisfaction and patient protection.
"Thanks to its broad spectrum, Simparica Trio helps veterinarians and dog owners provide more complete parasite coverage with a single-monthly chewable tablet. The broad spectrum of Simparica Trio minimises the potential risk of parasite protection gaps."
Simparica Trio is indicated for dogs from at least eight weeks of age and 1.25 kg and will be available in six tablet strengths for dogs of all sizes.
For more information about Simparica Trio and full prescribing information, visit www.zoetis.com.
Surrey vet Matthew Morgan has been struck off by the RCVS Disciplinary Committee after being convicted and imprisoned for four counts of pet insurance fraud.
Mr Morgan was convicted, upon his own confession, of dishonestly making false representations to make gain for himself/another or to cause loss to other/ expose other to risk on 22 July 2013 at the Central Criminal Court and, on 23 August 2013, was sentenced to two years' imprisonment.
The Disciplinary Committee heard that Mr Morgan, who was not present at the hearing but represented by Mr Laurence Imrie, Solicitor Advocate, had, between 13 November 2009 and 21 December 2012, taken out 18 insurance policies for veterinary cover with four separate insurance providers - Direct Line, Pet Plan, Pet Protect and Sainsbury's - in relation to a number of pets. Of these pets, only one, namely his pet cat, actually existed - the rest were fictitious.
During this period, the respondent made 50 claims on the insurance policies, seeking payment to reimburse him for the cost of veterinary treatment for the fictitious animals and also making false claims for treatment for his own pet cat, including for invented injuries 'sustained' during a non-existent car accident. As a result of the claims, the insurance companies made 54 payments to Mr Morgan to which he was not entitled, totalling £198,295.
At the time he began committing the offences Mr Morgan was working as a veterinary surgeon at a practice in Kent and, in order to support his fraudulent claims, used the practice's official stationery and stamps to fabricate invoices, clinical records and insurance claims. He continued to make fraudulent claims after leaving the practice, having taken the practice's headed paper and stamp with him.
Mr Morgan's actions came to light in December 2012 after submitting a claim to Direct Line for an operation on the spine of his own cat. The insurance company became suspicious and contacted the Kent practice which confirmed he had not treated the cat. An investigation by the insurers and, subsequently, the police began.
On 31 December 2012 Mr Morgan voluntarily attended a police station where he admitted fraudulently claiming £5,534.52 from Pet Plan and £7,610.03 from Direct Line, citing financial pressure caused by divorce, but failed to admit to the rest of his fraudulent activities. He was arrested on 25 January 2013 and, upon searching his home, police found the stamp and headed paper along with documents relating to the insurance claims.
The Disciplinary Committee, in considering the conduct of Mr Morgan, took into account a number of serious aggravating factors. This included the very high degree of financial gain from the fraudulent activities, the fact that there were 50 separate premeditated acts of dishonesty over a three-year period, the betrayal of trust of his former employer and the insurance companies, the potential reputational risk for his former employer, the abuse of his position as a veterinary surgeon and the fact that completion of insurance claims is an act of veterinary certification.
The Committee also considered, in mitigation, a letter from Mr Morgan to the Committee, three testimonials and representation from his legal representative. These cited the fact that Mr Morgan, when he committed the fraudulent activities, was heavily in debt, had serious domestic difficulties and was suffering from depression, although no medical evidence was submitted to the Committee.
However, it was the Committee's decision that the sanction of removing Mr Morgan from the Register had to be taken, in order to protect animal welfare and maintain public confidence in the profession.
Chairing and speaking on behalf of the Disciplinary Committee its Vice-Chairman, Ms Judith Webb, said: "The Committee is of the view that the Respondent's conduct in this case was deplorable ... Such conduct can only undermine public confidence in the profession. The Respondent abused his position as a veterinary surgeon to perpetrate a deliberate long-term fraud on insurers for personal gain.
"The Committee is conscious that its role is not to punish but to protect animal welfare and maintain public confidence in the profession. Due to the serious nature of the matters before it...the Committee has no doubt that the only suitable sanction is to direct the Registrar to remove the Respondent's name from the Register."
The Committee's full findings and decision are available on the RCVS website (www.rcvs.org.uk/disciplinary).
Lead surgeon at Roundhouse, Ross Allan (pictured right), an RCVS Advanced Practitioner in Small Animal Surgery, said: "We know many practitioners and clients have been frustrated by the difficulties in availability of TPLO in Scotland and we wanted to change that.
"As with our other Roundhouse Referral offerings, we have done away with long waiting lists, unpredictable pricing, and challenges in clinical continuity. We know that in doing so we will revolutionise access to this service and the experience of its users.
"Our TPLO service offers excellent value and quality – we have invested heavily in the very best DePuy Synthes TPLO plates and implants and, together with our hospital status, standards and track record, we are offering a premier TPLO service in Scotland: a TPLO with a recovery that is as reliable and predictable as our Fixed Price!"
The fixed prices for a TPLO are £3000 for dogs under 40kg and £3100 for dogs over 40kg.
The price includes the consultation, diagnostic X-rays/assessment, pre-surgical blood samples, hospitalisation, anaesthesia, surgery (including implants), follow up consultation and follow up X-rays.
Ross added: "We don’t expect anything to go wrong, but should we need to revise our surgery we would do so at no additional cost to the client – that’s our Fixed-Price Fix!"
To make an enquiry, or refer a patient for a Fixed Price Fix TPLO contact Roundhouse Referrals at 0141 649 1316 www.rhr.vet